Spinal proinflammatory cytokines are powerful pain-enhancing signals that contribute to pain following peripheral nerve injury (neuropathic pain). Recently, one proinflammatory cytokine, interleukin-1, was also implicated in the loss of analgesia upon repeated morphine exposure (tolerance). In contrast to prior literature, we demonstrate that the action of several spinal proinflammatory cytokines oppose systemic and intrathecal opioid analgesia, causing reduced pain suppression. In vitro morphine exposure of lumbar dorsal spinal cord caused significant increases in proinflammatory cytokine and chemokine release. Opposition of analgesia by proinflammatory cytokines is rapid, occurring 65 min after intrathecal (perispinal) opioid administration. We document that opposition of analgesia by proinflammatory cytokines cannot be accounted for by an alteration in spinal morphine concentrations. The acute anti-analgesic effects of proinflammatory cytokines occur in a p38 mitogen-activated protein kinase and nitric oxide dependent fashion. Chronic intrathecal morphine or methadone significantly increased spinal glial activation (toll-like receptor 4 mRNA and protein) and the expression of multiple chemokines and cytokines, combined with development of analgesic tolerance and pain enhancement (hyperalgesia, allodynia). Statistical analysis demonstrated that a cluster of cytokines and chemokines was linked with pain-related behavioral changes. Moreover, blockade of spinal proinflammatory cytokines during a stringent morphine regimen previously associated with altered neuronal function also attenuated enhanced pain, supportive that proinflammatory cytokines are importantly involved in tolerance induced by such regimens. These data implicate multiple opioid-induced spinal proinflammatory cytokines in opposing both acute and chronic opioid analgesia, and provide a novel mechanism for the opposition of acute opioid analgesia.
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Introduction
Evidence has recently accrued that repeated morphine administration induces the release of the proinflammatory cytokine, interleukin-1b (IL-1b), which opposes morphine analgesia (Johnston et al., 2004; Shavit et al., 2005) . This is generally believed to be due to a progressive activation of spinal cord glia in response to repeated morphine (Song and Zhao, 2001; Watkins et al., 2005) . Whether the release of IL-1 or other such proinflammatory mediators within spinal cord also contributes to the opposition of acute morphine analgesia is currently unknown. Likewise, the mechanism(s) by which acute opioids may induce proinflammatory mediators is unknown. While nitric oxide (NO) induced p38 mitogen-activated protein kinase (MAPK) activation in microglia has been implicated in decreased analgesia following repeated morphine (Cui et al., 2006; Liu et al., 2006) , no parallel information exists as to the acute effects of morphine.
The present series of experiments explores several questions regarding the spinal proinflammatory effects of morphine, the prototypical opioid. Firstly, is a proinflammatory response restricted to morphine, a 4,5-epoxymorphinan, versus may it be a more generalized response to opioids from other opioid structural classes? Secondly, how rapidly does opioid-induced proinflammatory cytokine responses occur and to what extent does this oppose opioid analgesia? Thirdly, what proinflammatory mediators are responsible for opposing acute and chronic opioid analgesia and do they oppose analgesia by altering morphine pharmacokinetics? Finally, are these proinflammatory mediators correlationally or causally linked with reductions in opioid analgesia? The present work seeks to address these questions firstly using a behavioral approach which tests the effects of antagonists of the proinflammatory mediators hypothesized to be involved in opposing opioid analgesia, and analyzes of mRNA
